Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge

This study has been completed.
Information provided by:
Palau Pharma S.A. Identifier:
First received: December 13, 2010
Last updated: April 14, 2011
Last verified: April 2011
The purpose of this study is to explore the activity of UR-63325 in a model of allergic rhinitis induced by nasal allergen challenge to known allergic rhinitis patients otherwise healthy.

Condition Intervention Phase
Seasonal Allergic Rhinitis
Drug: UR-63325
Drug: Fluticasone propionate nasal spray
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Double Blind Randomised Placebo and Active Controlled, Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge to Allergic Patients Otherwise Healthy

Resource links provided by NLM:

Further study details as provided by Palau Pharma S.A.:

Primary Outcome Measures:
  • Nasal and ocular symptoms scores after nasal allergen challenge [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Inflammatory parameters measured from nasal exudate [ Time Frame: 24 hours ] [ Designated as safety issue: No ]

Estimated Enrollment: 24
Study Start Date: December 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: UR-63325 Drug: UR-63325
Active Comparator: Fluticasone propionate nasal spray Drug: Fluticasone propionate nasal spray
Fluticasone propionate nasal spray
Placebo Comparator: Placebo Drug: Placebo
Placebo to UR 63325 and fluticasone propionate nasal spray


Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of written informed consent to participate (prior to any study-related procedures being performed) as shown by a signature on the volunteer consent form and to be able to adhere to the study restrictions and examination schedule
  • Subjects with confirmed history of seasonal allergic rhinitis to grass pollen (by direct questioning of presence of positive skin prick test to pollen and History of Symptoms of allergic rhinitis) within the previous two years
  • Positive skin prick test to timothy grass pollen (wheal difference with negative control ≥ 3 mm) at screening
  • Subjects with positive response to screening nasal challenge with increasing doses of timothy grass pollen (Symptoms worsening with respect to the response to the diluent challenge of ≥4 points in the total nasal symptom score [TNSS]) within one hour after last nasal allergen challenge
  • Screening and baseline FEV1 >80% predicted and FEV1/FVC > 70% predicted

Exclusion Criteria:

  • Symptoms of allergic rhinitis within 2 weeks prior to screening
  • Upper respiratory infection or sinusitis within 14 days of screening and also within 14 days of study start in each of the two periods
  • Structural nasal abnormalities or nasal polyps on examination, a history of nose bleeding or recent nasal surgery
  • History of asthma or asthmatic symptoms or other respiratory disease other than rhinitis within the last 2 years or FEV1<80% of predicted at screening or baseline
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01260753

Parexel International GmbH
Berlin, Germany, 14050
Sponsors and Collaborators
Palau Pharma S.A.
Principal Investigator: Rainard Fuhr, MD Parexel International GmbH
  More Information

Responsible Party: Roser Vives MD, Clinical Research Scientist, Palau Pharma S.A. Identifier: NCT01260753     History of Changes
Other Study ID Numbers: PPh/00071/10  2010-021858-20 
Study First Received: December 13, 2010
Last Updated: April 14, 2011
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Additional relevant MeSH terms:
Rhinitis, Allergic
Rhinitis, Allergic, Seasonal
Hypersensitivity, Immediate
Immune System Diseases
Nose Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Respiratory Tract Diseases
Respiratory Tract Infections
Anti-Allergic Agents
Anti-Asthmatic Agents
Anti-Inflammatory Agents
Autonomic Agents
Bronchodilator Agents
Dermatologic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Respiratory System Agents processed this record on May 26, 2016